Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... June 26, 2015  A San Francisco company, Pembient, ... with synthetic rhino horn: beer in China ... . In response to the emerging industry, two ... and sale of synthetic rhino horn.  ... Save the Rhino International (SRI) released a ...
(Date:6/26/2015)... , ... June 26, 2015 , ... ... services and a subsidiary of OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that ... as part of its Gut Microbiome Grant Program. The company has awarded its ...
(Date:6/25/2015)... 25, 2015 ... announced the addition of the  "2015 ... Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, ... Commercial Labs, POC Locations"  report ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , A ...
(Date:6/25/2015)... June 25, 2015  BioMed Realty Trust, Inc. (NYSE: ... ILMN ), a world leader in genomics focused ... the genome, has signed a 20-year lease for a ... in Cambridge, England . The project ... the highly skilled workforce in the dynamic research cluster ...
Breaking Biology Technology:Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 3Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 2Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 3BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 2BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 3
... Psylin Neurosciences Inc., a joint venture ... and PsychoGenics, Inc. announced today that it has ... for the treatment of depression.(Logo: ... from Amylin,s proprietary polypeptide hormone library, PHORMOL, was ...
... recent publication in Nature Photonics , a joint ... Center DIPC, Centro de Fsica de Materiales of CSIC/UPV-EHU ... Max Planck Institute of Biochemistry in Munich (Germany) reports ... by adopting tuning concepts from radio-frequency technology. The method ...
... available in German . , The ... is able to rapidly ,and efficiently detoxify chemical warfare ... Tokyo subway attacks in 1995. A detailed understanding ,of ... ,necessary for efforts aiming to improve their properties. A ...
Cached Biology Technology:Psylin Neurosciences Commences Development of Compound for Depression 2Psylin Neurosciences Commences Development of Compound for Depression 3Bridging the gap in nanoantennas 2Bridging the gap in nanoantennas 3Structure of enzyme against chemical warfare agents determined 2
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market announces that its Wocket® smart wallet will be the ... scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive one ... Inc.,s CEO Gino Pereira will be discussing its ...
(Date:6/17/2015)... 17, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced that Xiaomi, one of the world,s largest ... ClearPad ® family of capacitive touchscreen solutions ... (DDICs) for its latest smartphones, the Xiaomi Mi ... full in-cell display solutions and DDICs in discrete ...
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... Ala. Dr. Jian Han, faculty investigator at the ... rapid response, molecular-level assay for swine flu, the current ... The test, which can confirm swine flu in less ... respiratory panel made available by Diatherix Laboratories. The ...
... smell and their appetite. If this happened to mosquitoes, ... and spread malaria. A team of Penn State entomologists ... mosquitoes and impair their sense of smell. Supported by ... Gates Foundation,s Grand Challenges Explorations Initiative, the researchers were ...
... Dengue fever is the most common infectious disease transmitted ... world are infected. Researchers at the Hygiene Institute at ... three-dimensional model of the location in the human cell ... insight into the exact process of viral replication and ...
Cached Biology News:HudsonAlpha investigator develops rapid response swine flu test 2Penn State entomologists seek fungus to blunt mosquitoes' sense of smell 2Visualizing virus replication in three dimensions 2
... The Neural Stem Cell Expansion Kit - Neurosphere ... neural stem cell expansion as neurospheres in ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... E. coli strain containing an overproducing clone ... Reverse Transcriptase catalyzes the polymerization of DNA ... Full-length copies of large mRNAs, >10 kb, ... a much lower RNase H activity than ...
... RQ1 RNase-Free DNase is a preparation ... or double-stranded DNA to produce 3-hydroxyl ... use in applications where maintaining the ... DNase is qualified for use with ...
Biology Products: